Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 ...

A new research paper was published in Oncotarget, Volume 16, on March 27, 2025, titled "Imipridones ONC201/ONC206 + RT/TMZ ...

Sunshine Biopharma (SBFM) has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA Lipid ...

Sunshine Biopharma Inc. has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA lipid nanoparticle (K1.1-mRNA-LNP) product as a novel therapeutic agent for ...

Detailed price information for Sunshine Biopharma (SBFM-Q) from The Globe and Mail including charting and trades.

A new study shows that MXene-based nanozymes enhance cancer treatment by combining catalytic activity with electrical pulses, ...

Following encapsulation in two specifically designed Lipid Nanoparticles, the resulting K1.1c-mRNA-LNP and K1.1d-mRNA-LNP were efficiently delivered to orthotopic engrafted HCC tumors in mice in a ...

The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...